Eli Lilly and Indiana University have teamed up in a $40 million agreement to expand access to clinical trials in Indiana. This collaboration will focus on Alzheimer’s disease, diabetes, cancer, and cell and gene therapy, benefiting patients and advancing research in the state’s life sciences industry. The partnership will also enhance trial infrastructure, improve neurological health access, and develop talent for the biotechnology and pharmaceutical sectors. IU’s Launch Accelerator for Biosciences will lead the university’s efforts in this initiative, combining academic expertise with Lilly’s innovative solutions. (Words: 92)

Read more at NASDAQ.: Eli Lilly And Indiana University Sign $40 Mln Agreement To Expand Clinical Trials In Indiana